書籍詳細

1. メタボリックシンドロームにおける高尿酸血症の疫学

P.14 掲載の参考文献

• 1) Culleton BF et al: Serum uric acid and risk for cardiovascular disease and death; the Framingham heart study. Ann Inter Med 131:7-13, 1999

• 2) Alderman MH et al: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34:144-150, 1999
  pubmed

• 3) Choi HK, Ford ES: Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442-447, 2007
  pubmed

• 4) Lohsoonthorn V et al: Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res 37:883-889, 2006
  pubmed

• 5) 足達 寿:疫学的に見た高尿酸血症の重要性〜田主丸研究からみた高尿酸血症動向〜. 医薬の門 48:397-400, 2008

• 6) 東浦勝浩ほか:メタボリックシンドロームにおける高尿酸血症の意義. 医学と薬学 57:169-171, 2007
  Medical*Online

• 7) Ishizaka N et al:Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 25:1038-1044, 2005
  pubmed

• 8) Kawamoto R et al:Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intern Med 45:605-614, 2006
  pubmed

• 9) Sui X et al:Uric acid and the development of metabolic syndrome in women and men. Metabolism 57:845-852, 2007

• 10) Ryu S et al:Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann Epidemiol 17:245-252, 2007
  pubmed

• 11) 辻 裕之, 原 茂子:メタボリックシンドロームと高尿酸血症. 高尿酸血症と痛風 16:25-29, 2008
  Medical*Online

• 12) Facchini F et al: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266:3008-3011, 1991
  pubmed

• 13) Tsunoda S et al: Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens 15:697-701, 2002

• 14) Fam AG: Gout, diet, and the insulin resistance syndrome. J Rheumatol 29:1350-1355, 2002
  pubmed

• 15) Nakagawa T et al: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625-F631, 2006

• 16) 藤森 新:メタボリックシンドロームにおける高尿酸血症とその管理. 日本臨床 64(増刊):438-444, 2006

2. 尿酸と脂肪組織機能〜メタボリックシンドローム診療の新しい視点〜

P.23 掲載の参考文献

• 1) Wigglesworth VB: Histochemical studies of uric acid in some insects. I. Storage in the fat body of Periplaneta americana and the action of the symbiotic bacteria. Tissue Cell 19:83-91, 1987

• 2) Hediger MA: Kidney function: gateway to a long life? Nature 417:393-395, 2002
  pubmed

• 3) Matsuzawa Y: Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3:35-42, 2006
  pubmed

• 4) Mandavilli A, Cyranoski D: Asia's big problem. Nat Med 10:325-327, 2004

• 5) Wang MY et al: Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome. Proc Natl Acad Sci USA 105:6139-6144, 2008
  pubmed

• 6) Enomoto A et al: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447-452, 2002
  pubmed

• 7) Maalouf NM et al: Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol 2:883-888, 2007
  pubmed

• 8) 辻 裕之ら:21年間の人間ドックデータからみる血清尿酸値および尿pHとメタボリックシンドローム関連諸因子との関係. 人間ドック 22:55-60, 2007

• 9) Cheung KJ et al: Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab 5:115-128, 2007
  pubmed

• 10) Price KL et al: Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 17:1791-1795, 2006
  pubmed

3. 尿酸と酸化ストレス

P.28 掲載の参考文献

• 1) Keaney JF Jr et al: Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23:434-439, 2003
  pubmed

• 2) Fujita K et al: Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 70:1437-1442, 2006
  pubmed

• 3) Palmieri VO et al: Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr 136:3022-3026, 2006
  pubmed

• 4) Furukawa S et al: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004
  pubmed

• 5) Ames BN et al: Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78:6858-6862, 1981
  pubmed

• 6) Muraoka S et al: Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol Toxicol 93:284-289, 2003
  pubmed

• 7) Davies KJ et al: Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235:747-754, 1986
  pubmed

• 8) Glantzounis GK et al: Uric acid and oxidative stress. Curr Pharm Des 11:4145-4151, 2005
  pubmed

• 9) Santos CX et al: Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 372:285-294, 1999
  pubmed

• 10) Abuja PM: Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett 446:305-308, 1999
  pubmed

• 11) Rao GN et al: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266:8604-8608, 1991
  pubmed

• 12) Kanellis J et al: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41:1287-1293, 2003
  pubmed

• 13) Kang DH et al: Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 25:425-433, 2005

• 14) Sautin YY et al: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxiddase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293:C584-596, 2007
  pubmed

• 15) Rudich A et al: Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 47:1562-1569, 1998
  pubmed

• 16) Tirosh A et al: Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 274:10595-10602, 1999
  pubmed

• 17) Krieger-Brauer HI et al: Human fat cells possess a plasma membrane-bound H2O2-generating system that is activated by insulin via a mechanism bypassing the receptor kinase. J Clin Invest 89:1006-1013, 1992

• 18) Matsuzawa Y et al: Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892:146-154, 1999
  pubmed

• 19) Tamba S et al: Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med 47:1175-1180, 2008
  pubmed

4. 尿酸とインスリン抵抗性

P.34 掲載の参考文献

• 1) Choi HK et al: Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. Rheumatology 47:713-717, 2008

• 2) Tamba S et al: Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med 47:1175-1180, 2008
  pubmed

• 3) Hikita M et al: Relationship between hyperuricemia and body fat distribution. Intern Med 46:1353-1358, 2007
  pubmed

• 4) Tuomilehto J et al: Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 127:321-336, 1988

• 5) Herman JB et al: Diabetes, prediabetes and uricaemia. Diabetologia 12:47-52, 1976
  pubmed

• 6) Perry IJ et al: Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ 1310:560-564, 1995

• 7) Bo S et al: Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest 31:318-321, 2001
  pubmed

• 8) Gotfredsen A et al: Renal hypouricaemia in insulin treated diabetes mellitus. Clin Chim Acta 120:355-361, 1982.
  pubmed

• 9) Quinones Galvan A et al: Effect of insulin on uric acid excretion in humans. Am J physiol 268:E1-5, 1995
  pubmed

• 10) Muscelli E et al: Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 9:746-752, 1996
  pubmed

• 11) Schenk S et al: Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118:2992-3002, 2008
  pubmed

• 12) Savage DB et al: Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 87:507-520, 2007
  pubmed

• 13) Kadowaki T et al: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed

• 14) Rasouli N et al: Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93:S64-73, 2008

5. 尿酸とアディポネクチン

P.41 掲載の参考文献

• 1) Maeda K et al: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1(Adipose most abundant gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 2) Maeda N et al: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 3) Matsuda M et al: Role of adiponectin in preventing vascular stenosis-the missing link of adipo-vascular axis-. J Biol Chem 277:37487-37491, 2002

• 4) Ryo M et al: Adiponectin as a biomarker of the metabolic syndrome. Circ J 68:975-981, 2004
  pubmed

• 5) Kumada M et al: Association of hypoadiponectinemia With coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003
  pubmed

• 6) Tamba S et al: Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med 47:1175-1180, 2008
  pubmed

• 7) 山田祐也ほか:メタボリックシンドロームにおける尿酸代謝とアディポネクチン濃度の関連. J Metabolic Syndrome 3:32-35, 2006

• 8) Bo S et al: Associations between serum uric acid and adipokines, markers of inflammation, and endothelial dysfunction. J Endocrinol Invest 31:499-504, 2008

• 9) Matsuura F et al: Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 47:929-933, 1998
  pubmed

• 10) Nakagawa T et al: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625-F631, 2005

6. 尿酸とメタボリックシンドローム (周辺疾患も含めて)

P.48 掲載の参考文献

• 1) 嶺尾郁夫:メタボリックシンドロームにおける高尿酸血症の病態意義:歴史的経緯から最近の知見まで. 痛風と核酸代謝 32:121-132, 2008

• 2) 嶺尾郁夫:肥満と高尿酸血症:動脈硬化症の成因をめぐる病態意義について. 治療 88: 2729-2735, 2006
  Medical*Online

• 3) Must A et al: Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 327:1350-1355, 1992
  pubmed

• 4) Roubenoff R et al: Incidence and risk factors for gout in white men. JAMA 266:3004-3007, 1991
  pubmed

• 5) Choi HK et al: Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 165:742-748, 2005
  pubmed

• 6) 嶺尾郁夫ほか:肥満と高尿酸血症. 高尿酸血症と痛風 7:108-114, 1999

• 7) Chang HY et al: Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. J Clin Nutr 79:31-39, 2004

• 8) Oyama C et al: Serum uric acid as an obesity-related indicator in early adolescence. Tohoku J Exp Med 209:257-262, 2006
  pubmed

• 9) Nakanishi N et al: Risk factors for the incidence of hyperuricaemia: a 6-year longitudinal study of middle-aged Japanese men. Int J Epidemiol 28:888-893, 1999
  pubmed

• 10) Masuo K et al: Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42:474-480, 2003
  pubmed

• 11) Scott JT, Sturge RA: The effect of weight loss on plasma and urinary uric acid and lipid levels. Adv Exp Med Biol 76B:274-277, 1977
  pubmed

• 12) Emmerson BT: Alteration of urate metabolism by weight reduction. Aust NZ J Med 3:410-412, 1973

• 13) Yamashita S et al: Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes 10:255-264, 1986
  pubmed

• 14) Matsuura F et al: Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 47:929-933, 1998
  pubmed

• 15) Lopez-Suarez A et al: Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome. Med Clin(Barc) 126:321-324, 2006 [Spanish]
  pubmed

• 16) Facchini F et al: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266:3008-3011, 1991
  pubmed

• 17) Ter Maaten JC et al: Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci(Lond) 92:51-58, 1997
  pubmed

• 18) Johnson RJ et al: Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 86:899-906, 2007
  pubmed

• 19) Brandstatter A et al: Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care 31:1662-1667, 2008
  pubmed

• 20) Shiraishi H et al: The effect of the interaction between obesity and drinking on hyperuricemia in Japanese male office workers. J Epidemiol 19:12-16, 2009

P.55 掲載の参考文献

• 1) Butler R et al: Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35:746-751, 2000
  pubmed

• 2) Dehghan A et al: High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31:361-363, 2008
  pubmed

• 3) Erdberg A et al: Urine uric acid excretion in patients with insulin-dependent diabetes mellitus, Nephron 60:134-137, 1992
  pubmed

• 4) Alexander M et al: Insulin regulation of protein biosythesis in differentiated 3T3 adipocytes; Regulation of glyceraldehydes-3-phosphate dehydrogenase. J Biol Chem 260:11978-11985, 1985

• 5) Kusner LL et al: Nuclear translocation of glyceraldehydes-3-phosphate dehydrogenase: A role in high glucose-induced apoptosis in retinal Muller cells. Invest Ophthalmol Vis Sci 45:1553-1561, 2004

• 6) Johnson RJ et al: Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 86:899-906, 2007
  pubmed

• 7) Underwood M: Diagnosis and management of gout. BMJ 332:1315-1319, 2006
  pubmed

• 8) Nakagawa T et al: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625-631, 2006

• 9) Kawasaki T et al: Increased fructose concentrations in blood and urine in patients with diabetes. Diabetes Care 25:353-357, 2002
  pubmed

P.63 掲載の参考文献

• 1) Feig DI et al: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300(8):924-932, 2008
  pubmed

• 2) Tykarski A: Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 59(3):364-368, 1991
  pubmed

• 3) Cannon PJ et al: Hyperuricemia in primary and renal hypertension. N Engl J Med 275(9):457-464, 1966
  pubmed

• 4) Johnson RJ et al: Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 16(7):1909-1919, 2005

• 5) 村上英之ほか:本態性高血圧患者におけるインスリン抵抗性と尿酸代謝. Therapeutic Research 22:1289-1292, 2001
  Medical*Online

• 6) Mazzali M et al: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38(5):1101-1106, 2001
  pubmed

• 7) Watanabe S et al: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40(3):355-360, 2002
  pubmed

• 8) Kanellis J et al: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41(6):1287-1293, 2003
  pubmed

• 9) Kang DH et al: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16(12):3553-3562, 2005

• 10) Kang DH et al: Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 25(5):425-433, 2005

• 11) Kato M et al: Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 96(11):1576-1578, 2005
  pubmed

• 12) 高尿酸血症・痛風の治療ガイドライン作成委員会:高尿酸血症・痛風の治療ガイドライン 第1版, 日本痛風・核酸代謝学会, 東京, 2002

• 13) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009

• 14) 浜田紀宏ほか:N型カルシウム拮抗薬シルニジピンの筋原性高尿酸血症抑制作用. 診断と新薬 43:382-386, 2006

• 15) Reyes AJ: Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 17(5-6):397-414, 2003

• 16) Iwanaga T et al: Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320(1):211-217, 2007
  pubmed

P.68 掲載の参考文献

• 1) Bickel C et al: Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89(1):12-17, 2002
  pubmed

• 2) Tsouli SG et al: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 55(10):1293-4301, 2006
  pubmed

• 3) Schmidt MI et al: Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism 45(6):699-706, 1996

• 4) Boyko EJ et al: Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care 23(9):1242-1248, 2000
  pubmed

• 5) See LC et al: Serum Uric Acid Is Independently Associated with Metabolic Syndrome in Subjects with and without a Low Estimated Glomerular Filtration Rate. J Rheumatol 36(8):1691-1698, 2009
  pubmed

• 6) 日本動脈硬化学会:動脈硬化性疾患予防ガイドライン2007年版, 東京, 2007

• 7) Ferrieres J: Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins. Am J Cardiovasc Drugs 9(2):109-115, 2009
  pubmed

• 8) Zavaroni I et al: Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia. J Intern Med 234(1):25-30, 1993
  pubmed

• 9) Facchini F et al: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266(21):3008-3011, 1991
  pubmed

• 10) Giacomello A et al: Relation between serum triglyceride level, serum urate concentration, and fractional urate excretion. Metabolism 46(9):1085-1089, 1997
  pubmed

• 11) Matsuura F et al: Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: Visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 47(8):929-933, 1998
  pubmed

• 12) Matsuzaki M et al: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66(12):1087-1095, 2002
  pubmed

P.78 掲載の参考文献

• 1) Ishizaka N et al: Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanease individuals. Arterioscler Thromb Vasc Biol 25:1038-1044, 2005

• 2) Fang J, Alderman MH: Serum uric acid and cardiovascular mortality, The NHANES 1 epidemiology follow-up study, 1971-1992. JAMA 283:2404-2410, 2000
  pubmed

• 3) Chen JH et al: Serum uric acid level as an independent risk factor for al1-cause, cardiovascular, and ischemic stroke mortality: A chinese cohort study. Arthritis Rheum. 61:225-232, 2009

• 4) Hoieggen A et al: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65:1041-1049, 2004
  pubmed

• 5) Lehto S et al: Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 29:635-659, 1998

• 6) Bickel C et al: Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89:12-17, 2002
  pubmed

• 7) Kojima S et al: Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 96:489-495, 2005
  pubmed

• 8) Wong KYK et al: Urate redicts subsequent cardiac death in stroke survivors. Eur Heart J 23:788-793, 2002

• 9) Sakai H et al: Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. Circ J 70:1006-1011, 2006
  pubmed

• 10) Facchini F et al: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266:3008-3011, 1991
  pubmed

• 11) Leyva F et al: The glycolytic pathway to coronary heart disease; A hypothesis. Metabolism 47:657-662, 1998
  pubmed

• 12) Furukawa S et al: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004
  pubmed

• 13) Underwood M: Sugary drinks, fruit, and increased risk of gout. BMJ 336:285-286, 2008
  pubmed

• 14) Hotamisligil GS et al: Adipose expression of tumor necrosis factor-α:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993

• 15) Tamba S et al: Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med 47:1175-1180, 2008
  pubmed

• 16) Johnson RJ et al: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183-1190, 2003

• 17) Farquharson CA et al: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106:221-226, 2002
  pubmed

• 18) Mazzali M et al: Hyperuricemia induces a primry renal arteriopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:F991-997, 2002

• 19) 高尿酸血症・痛風の治療ガイドライン作成委員会:日本痛風・核酸代謝学会高尿酸血症・痛風の治療ガイドライン(第1版), 日本痛風・核酸代謝学会, 東京, 2002

P.87 掲載の参考文献

• 1) 日本腎臓学会:CKD診療ガイド2009. 東京, 東京医学社, 2009

• 2) 日本透析医学会:図説 わが国の慢性透析療法の現況2008年12月31日現在, 2009

• 3) Enomoto A et al: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447-452, 2002
  pubmed

• 4) Vaziri ND et al: Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 6:1313-1317, 1995
  pubmed

• 5) Ohno I et al: Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 87:333-339, 2001
  pubmed

• 6) Syrjanen J et al: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15:34-42, 2000
  pubmed

• 7) Iseki K et al: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44:642-650, 2004

• 8) Weiner DE et al: Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19:1204-1211, 2008

• 9) Rudolf P et al: Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 19:2407-2413, 2008

• 10) Johnson RJ et al: Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 16:1909-1919, 2005

• 11) Siu YP et al: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51-59, 2006
  pubmed

• 12) 内田俊也:慢性腎臓病(CKD)に合併する高尿酸血症に対するベンズブロマロンの臨床的有用性の検討. 医学と薬学 57:879-882, 2007
  Medical*Online

• 13) Kanbay M et al: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39:1227-1233, 2007

• 14) 大野岩男ほか:腎機能障害を合併する痛風・高尿酸血症症例におけるアロプリノール・ベンズブロマロン併用療法の有用性 オキシプリノール動態の検討から. 日腎会誌 50(4):506-512, 2008

P.95 掲載の参考文献

• 1) 日本肝臓学会編:NASH・NAFLDの診療ガイド, 文光堂, 2006

• 2) Ludwig J et al: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-438, 1980

• 3) 西原利治編:NASH診療 best approach, 中外医学社, 2008

• 4) 日本痛風・核酸代謝学会編:高尿酸血症・痛風の治療ガイドライン. http://www. tukaku. jp/guideline. pdf

• 5) Tsouli SG et al: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 55:1293-1301, 2006
  pubmed

• 6) Suzuki I et al: Allopurinol, an inhibitor of uric acid synthesis-Can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today (Barc) 45:363-368, 2009

• 7) Taha MO et al: Effects of allopurinol on ischemia and reperfusion in rabbit livers. Transplant Proc 41:820-823, 2009
  pubmed

7. メタボリックシンドロームにおける高尿酸血症の管理と薬物療法

P.102 掲載の参考文献

• 1) Choi HK et al: Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277-1281, 2004

• 2) Lieber CS: Hyperuricemia induced by alcohol. Arthritis Rheum 8(5):786-798, 1965
  pubmed

• 3) Faller J, Fox IH: Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med 307(26):1598-1602, 1982
  pubmed

• 4) Puig JG, Fox IH: Ethanol-induced activation of adenine nucleotide turnover. Evidence for a role of acetate. J Clin Invest 74(3):936-941, 1984
  pubmed

• 5) Yamamoto T et al: Effect of ethanol ingestion on nucleotides and glycolytic intermediates in erythrocytes and purine bases in plasma and urine: acetaldehyde-induced erythrocyte purine degradation. Metabolism 42(9):1212-1216, 1993
  pubmed

• 6) Masson S et al: The effects of ethanol concentration on glycero-3-phosphate accumulation in the perfused rat liver. A reassessment of ethanol-induced inhibition of glycolysis using 31P-NMR spectroscopy and HPLC. Eur J Biochem 205(1):187-194, 1992
  pubmed

• 7) Yamamoto T et al: The role of acetaldehyde and erythrocyte aldehyde dehydrogenase in acetaldehyde-induced erythrocyte purine degradation. Jap J Rheumatology 5:355-361, 1995

• 8) Yamamoto T et al: Effect of beer on the plasma concentrations of uridine and purine bases. Metabolism 51(10):1317-1323, 2002
  pubmed

• 9) Yamamoto T et al: Effect of purine-free low-malt liquor(happo-shu) on the plasma concentrations and urinary excretion of purine bases and uridine-comparison betWeen purine-free and regular happo-shu. Horm Metab Res 36(4):231-237, 2004
  pubmed

• 10) Yamamoto T et al: Effect of ethanol on metabolism of purine bases(hypoxanthine, xanthine, and uric acid). Clin Chim Acta 356(1-2):35-57, 2005
  pubmed

• 11) Yamamoto T et al: Effect of ethanol and fructose on plasma uridine and purine bases. Metabolism 46:544-547, 1997
  pubmed

• 12) Choi HK, Curhan G: Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336(7639):309-312, 2008
  pubmed

• 13) Matsuura F et al: Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 47(8):929-933, 1998
  pubmed

• 14) Takahashi S et al: Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Metabolism 46(10):1162-1165, 1997
  pubmed

• 15) Cheung KJ et al: Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab 5(2):115-128, 2007
  pubmed

• 16) Facchini F et al: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266(21):3008-3011, 1991
  pubmed

• 17) Ogryzlo MA: Hyperuricemia induced by high fat diets and starvation. Arthritis Rheum 8(5):799-822, 1965
  pubmed

• 18) Fox IH et al: Hyperuricemia and hypertriglyceridemia: metabolic basis for the association. Metabolism 34:741-746, 1985
  pubmed

• 19) Yamamoto T et al: Effect of amino acids on the plasma concentration and urinary excretion of uric acid and uridine. Metabolism 48:1023-1027, 1999
  pubmed

• 20) Choi HK et al: Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 52(1):283-289, 2005
  pubmed

P.107 掲載の参考文献

• 1) 伊藤朗ほか:各種運動時の血清尿酸値の動態. 尿酸 8:38-47, 1984

• 2) 小笠原正志ほか:運動強度の差がammoniaおよびoxypurine動態に及ぼす影響. 体力化学 37:85-92, 1988

• 3) 山中 寿:痛風・高尿酸血症の運動療法. 今月の治療 3:845-854, 1995

• 4) Yamanaka H et al: Accelerated purine nucleotide degradation by anaerobic but not by aerobic ergometer muscle exercise. Metabolism 41:364-369, 1992

• 5) Davis JA et al: Anaerobic threshold and maximal aerobic power for three modes of exercise. J Appl Physiol 41:544-550, 1976
  pubmed

• 6) 伊藤 朗:高尿酸血症の運動処方. 日本臨牀 58(増刊号):431-436, 2000

• 7) Enomoto A et al: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447-52, 2002
  pubmed

• 8) Lin WL et al: High prevalence of hyperuricemia in Taiwanese professional and collegiate athletes. J Clin Rheumatol 12:159-160, 2006
  pubmed

• 9) Williams PT: Relationship of distance run per week to coronary heart disease risk factors in 8283 male runners. The National Runners` Health Study. Arch Intern Med 157:191-198, 1997
  pubmed

• 10) Lippi G et al: Comparison of serum creatinine, uric acid, albumin and glucose in male professional endurance athletes compared with healthy controls. Clin Chem Lab Med 42:644-647, 2004
  pubmed

• 11) 細谷龍男ほか:長距離走による尿酸代謝の動態と性差. プリン・ピリミジン代謝 18:11-17, 1994

• 12) 橋詰直孝ほか:長距離・マラソンランナーの血清尿酸値の動態と意義. プリン・ピリミジン代謝 16:93-97, 1992

• 13) 伊藤 朗ほか:高尿酸血症の運動処方に関する研究-最大運動後の軽運動が運動性高尿酸血症に及ぼす影響-. 筑波大学体育科学系紀要 16:99-106, 1993

P.114 掲載の参考文献

• 1) 高尿酸血症・痛風の治療ガイドライン作成委員会編:高尿酸血症・痛風の治療ガイドライン 第1版. 日本痛風・核酸代謝学会, 東京, 2002

• 2) 中村 徹:高尿酸血症の成因と病態. 実地医家のための高尿酸血症・痛風の診療(中村 徹 編), メディカルレビュー社, 大阪, 2001, pp21-38

• 3) Shoji A et al: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51:321-325, 2004
  pubmed

• 4) Li-Yu J et al: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28:577-580, 2001

• 5) Nickeleit V, Mihatsch MJ: Uric acid nephropathy and end-stage renal disease-Review of a non-disease. Nephrol Dial Transplant 12:1832-1838, 1997
  pubmed

• 6) Abate N et al: The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestation of insulin resistance. Kidney Int 65:386-392, 2004
  pubmed

• 7) Okabe H et al: Analysis of urolithiasis in patients with gout and hyperuricemia using ultrasonography. Jpn J Rheum 9:239-244, 1999